Cingulate
$5.10
48
-$0.12-2.3% Friday 20:00
-$0.06-1.15%Friday 21:40After hours
Statistics
Day High
5.1
Day Low
5.08
52W High
11.89
52W Low
3.16
Volume
3,115
Avg. Volume
-
Mkt Cap
74.16M
P/E Ratio
-
Dividend Yield
-
Dividend
-
Upcoming
Earnings
18NovExpected
Q3 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-2.36
-1.73
-1.09
-0.45
Expected EPS
-0.48
Actual EPS
N/A
Financials
-Profit Margin
Unprofitable0Revenue
-22.45MNet Income
Analyst Ratings
24.33Average Price Target
The highest estimate is 44.00.
From 3 ratings within the last 6 months. This is not an investment recommendation.
From 3 ratings within the last 6 months. This is not an investment recommendation.
Buy 100%
Hold 0%
Sell 0%
People Also Follow
This list is based on the watchlists of people on Stock Events who follow CING. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
Supernus Pharmaceuticals
SUPN
Mkt Cap2.54B
Takeda Pharmaceutical
TAK
Mkt Cap57.58B
Johnson & Johnson
JNJ
Mkt Cap645.95B
Novartis
NVS
Mkt Cap292.35B
Pfizer
PFE
Mkt Cap159.36B
Lilly(Eli) &
LLY
Mkt Cap1.05T
Teva- Pharmaceutical Industries
TEVA
Mkt Cap42.46B
Merck
MRK
Mkt Cap366B
About
Cingulate Inc is a clinical-stage biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety. The Company is developing two proprietary, first-line stimulant medications, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents, and adults. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.
Show more...
CEO
Shane J. Schaffer
Employees
14
Country
United States
ISIN
US17248W3034
Listings
0 Comments
Share your thoughts
FAQ
What is Cingulate stock price today?▼
The current price of CING is $5.10 USD — it has decreased by -2.3% in the past 24 hours. Watch Cingulate stock price performance more closely on the chart.
What is Cingulate stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Cingulate stocks are traded under the ticker CING.
Is Cingulate stock price growing?▼
CING stock has fallen by -4.23% compared to the previous week, the month change is a +3.24% rise, over the last year Cingulate has showed a +30.77% increase.
What is Cingulate market cap?▼
Today Cingulate has the market capitalization of 74.16M
When is the next Cingulate earnings date?▼
Cingulate is going to release the next earnings report on November 18, 2026.
What were Cingulate earnings last quarter?▼
CING earnings for the last quarter are -0.45 USD per share, whereas the estimation was -0.63 USD resulting in a +28% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Cingulate revenue for the last year?▼
Cingulate revenue for the last year amounts to 0 USD.
What is Cingulate net income for the last year?▼
CING net income for the last year is -22.45M USD.
How many employees does Cingulate have?▼
As of September 05, 2026, the company has 14 employees.
In which sector is Cingulate located?▼
Cingulate operates in the Health & Wellness sector.
When did Cingulate complete a stock split?▼
The last stock split for Cingulate was on August 09, 2024 with a ratio of 1:12.
Where is Cingulate headquartered?▼
Cingulate is headquartered in KANSAS CITY, United States.